Evonik Industries: Investors suffer from price declines and warning signals!

Evonik Industries: Investors suffer from price declines and warning signals!

Evonik Industries AG has seen a significant decline in its share price over the last five years, amounting to 33%. Loud Simply Wall The company experienced a further decline of 14% in the last quarter. In contrast, the overall market only fell by 5.7% during this period.

However, the company's development also has positive aspects. Evonik achieved profitability in these five years and the dividend remained stable, raising questions about the cause of the share price decline. It is noted that Evonik Industries' total shareholder return (TSR) over the last five years is -9.8%, which is worse than the share price return.

Market developments and investor behavior

Last year, investors suffered a total loss of 1.2% (including dividends), while the market gained about 26% over the same period. Long-term shareholders have suffered a loss of 1.9% over the last five years. There is also currently one warning sign in Evonik Industries' investment analysis, which should alert potential investors.

The price of Evonik shares is currently EUR 16.74, which corresponds to a decrease of 0.48% compared to the previous trading day. On August 11, 2025, the stock closed at EUR 16.82, a loss of 1.58%, following a close of EUR 17.09 on August 8, 2025, up 1.24%, and an increase of 2.55% on August 7, 2025.

Financial indicators and company profile

The market value of Evonik Industries is EUR 7.84 billion, while the company expects sales of EUR 14.35 billion and net income of EUR 542 million in 2025. The price-earnings ratio (P/E) for 2025 is 14.4x and for 2026 is 12.4x. In addition, net debt of EUR 3.28 billion is expected for 2025 and EUR 3.8 billion for 2026. The return for 2025 is estimated at 6.96% and for 2026 at 7.01%.

Evonik Industries AG, based in Germany, specializes in specialty chemicals and operates in the development, construction and distribution of scientific equipment and chemicals for life sciences and biotechnology. The average price target for the stock is EUR 20.71, implying a potential increase of 23.11% compared to the last closing price. Further details on the current market situation are available here MarketScreener to find.